Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
information fournie par Boursorama 07/01/2020 à 07:30

- TG4050 moves therapeutic vaccination into the digital age: combines Transgene's expertise in viral vectors with NEC's cutting-edge Artificial Intelligence (AI) capabilities
- Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations
- First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole


Strasbourg, France & Tokyo, Japan, January 7, 2020, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT and network technologies, today announced that the first patients have been enrolled in the first-in-human trials evaluating TG4050, an individualized therapeutic vaccine based on the myvac(TM) technology and powered by NEC's cutting-edge AI capabilities. In these Phase 1 trials, TG4050 is being administered to patients with head and neck cancer who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy.

Valeurs associées

TRANSGENE
0,8270 EUR Euronext Paris -0,96%
Le présent contenu est proposé par Boursorama. Cet article ou cette vidéo ne doivent en aucun cas s'apparenter à un conseil en investissement ou une recommandation d'acheter, de vendre ou de continuer à détenir un investissement. Boursorama ne saurait être tenue responsable d'une décision d'investissement ou de désinvestissement sur la base de cet article ou de cette vidéo.

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 005,78 +0,30%
Pétrole Brent
109,18 -1,57%
SOITEC
156,7 +9,47%
HAFFNER ENERGY
0,153 +10,39%
NANOBIOTIX
36,48 -5,20%
Chargement...

Pages les plus populaires

L'offre BoursoBank